Loading...
We would love for you to become a part of our community. Join our Discord to connect with us and other members!
- Ticker
- SANN.SW
- Price
- 17.12
- Stock movement up
- +0.72 (4.39%)
- Company name
- Santhera Pharmaceuticals Holding AG
- Exchange
- (SW ,
- Currency
- CHF )
- Sector
- Healthcare >Biotechnology
- Market cap
- 207.26M
- Ent value
- 250.95M
- Price/Sales
- 1.22
- Price/Book
- 4.31
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 2.03
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 74.69%
- 3 year return
- 126.67%
- 5 year return
- 10.48%
- 10 year return
- -15.97%
Last updated: 2025-02-01
DIVIDENDS
SANN.SW does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 2.03 |
| Price to OCF | 4.38 |
| Price to FCF | 3.76 |
| Price to EBITDA | 2.19 |
| EV to EBITDA | 2.65 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.22 |
| Price to Book | 4.31 |
| EV to Sales | 1.47 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 12.11M |
| EPS (TTM) | 8.99 |
| FCF per share (TTM) | 4.86 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 170.33M |
| Gross profit (TTM) | 162.82M |
| Operating income (TTM) | 88.82M |
| Net income (TTM) | 101.91M |
| EPS (TTM) | 8.99 |
| EPS (1y forward) | -3.14 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 95.59% |
| Operating margin (TTM) | 52.15% |
| Profit margin (TTM) | 59.83% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 16.49M |
| Net receivables | 10.43M |
| Total current assets | 33.64M |
| Goodwill | 0.00 |
| Intangible assets | 71.45M |
| Property, plant and equipment | 0.00 |
| Total assets | 108.25M |
| Accounts payable | 14.91M |
| Short/Current long term debt | 26.37M |
| Total current liabilities | 53.05M |
| Total liabilities | 60.19M |
| Shareholder's equity | 48.06M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 47.35M |
| Capital expenditures (TTM) | 162.00K |
| Free cash flow (TTM) | 55.07M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 212.07% |
| Return on Assets | 94.15% |
| Return on Invested Capital | 141.56% |
| Cash Return on Invested Capital | 76.49% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 16.40 |
| Daily high | 17.30 |
| Daily low | 16.40 |
| Daily Volume | 92K |
| All-time high | 134.40 |
| 1y analyst estimate | 25.00 |
| Beta | 0.13 |
| EPS (TTM) | 8.99 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 23 Apr 2025 |
Downside potential
Loading...
Downside potential data
| SANN.SW | S&P500 | |
| Current price drop from All-time high | -87.26% | -1.30% |
| Highest price drop | -99.63% | -56.47% |
| Date of highest drop | 2 Dec 2022 | 9 Mar 2009 |
| Avg drop from high | -75.70% | -11.10% |
| Avg time to new high | 647 days | 12 days |
| Max time to new high | 2356 days | 1805 days |
COMPANY DETAILS
Marketcap
207.26M
Marketcap category
Small-cap
Description
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
Employees
44
Website
Investor relations
-
SEC filings
CEO
Country
Switzerland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare Fun...
January 16, 2025
Santhera has begun launch preparations for AGAMREE® in UK with first sales expected in this quarter Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that the Na...
January 16, 2025
AGAMREE® is approved by MHRA for treating Duchenne muscular dystrophy (DMD) in patients 4 years of age and older in UKPratteln, Switzerland, January 14, 2025 – Santhera Pharmaceuticals (SIX: SANN) ann...
January 14, 2025
Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group
Pratteln, Switzerland, January 6, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vam...
January 6, 2025
Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older Follows recent approval from China’s National Medica...
December 20, 2024
China’s National Medical Products Administration (NMPA) approved AGAMREE® for the treatment of Duchenne muscular dystrophy in patients aged 4 years and olderThis approval makes AGAMREE the first and o...
December 11, 2024
AGAMREE® has been recommended by NICE for treating Duchenne muscular dystrophy (DMD) in patients 4 years of age and older in England, Wales and Northern IrelandSanthera will be working closely with NH...
December 10, 2024
Pratteln, Switzerland, November 12, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive supply agreement with Ali Al Suwaidi Trading Est. (ASTE) for the treatment of pati...
November 12, 2024
Pratteln, Switzerland, October 1, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the positive outcome of the LIONHEART study, confirming vamorolone’s distinctive action also as a mineralocortic...
October 1, 2024
Pratteln, Switzerland, September 24, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that Swissmedic, the Swiss Agency for Therapeutic Products, has accepted for review the marketing authorizati...
September 24, 2024
Next page